After surging on lung cancer data, Ignyta looks to raise $160m
October 20, 2017
uniQure presses ‘refresh’ on haemophilia gene therapy, gets FDA blessing
October 19, 2017Biotech has been in talks with US and EU regulators
Navigating the barriers to successful market access
October 18, 2017The steps required for successful market access.
Rare disease market research needs a multifaceted approach
October 17, 2017Challenges in rare disease market research and the role of online research.
Navigating the barriers to successful market access
October 18, 2017The steps required for successful market access.
Keeping ahead of the curve
October 12, 2017Jon Williams, President of Evidera, is well-placed to offer his views on the issues impacting access to therapies.
PRIME movers: taking stock of the EMA’s scheme
October 4, 2017Taking stock of one PRIME, of the EMA’s flagship market access initiatives.
11/06/2017
Improving Outcomes Through Industry Partnership – Learnings from the Cancer Vanguard
August 29, 2017
Pricing and market access – facts versus fiction
January 31, 2017‘Pricing and Market Access Outlook: 2017 Edition’ includes fresh analysis from QuintilesIMS of market forces and pricing policy based on facts and figures behind approvals of new molecular entities in 2015.
Healthcare in the Digital Age
November 22, 2016A new whitepaper presenting analysis of exclusive M3 (EU) data, revealing the digital and technological habits and preferences of doctors and how pharma can best engage.
Being Patient-centric is being Family-centric
March 30, 2015
Patient Opinion Leaders: Andrew Schorr
August 8, 2014Press releases
Placing the patient at the centre
October 18, 2017
How to fix your adherence problem
October 18, 2017
Can parallel distribution and industry work together?
October 17, 2017
Appointments
Makara Health bolsters team with new hires
September 28, 2017
